Characterization of the microVAScular Dysfunction in Covid-19 ARDS (VASCOV)

Assistance Publique - Hôpitaux de Paris

Status: Unknown

Conditions: COVID-19 Acute Respiratory Distress Syndrome; ARDS, Human

Treatments: Diagnostic Test: Endothelial activation / endothelial senescence; Diagnostic Test: alveolar dead-space quantification; Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations

Study type: Observational

Funder types: Other

Identifiers

NCT05074758

APHP210693

2021-A01339-32 (Other Identifier)

Details and patient eligibility

About

The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.

Secondarily, the investigators want to establish the prognostic value of the alveolar-dead space (measured iteratively) in patients with COVID-19 and non-COVID-19 ARDS, to establish the respective influences of the biological parameters of endothelial damage, of the biological parameters of coagulopathy, of the parameters set on the artificial ventilator on the value of the alveolar dead space; in ARDS patients with COVID-19 and non-COVID-19 ARDS, to establish the prognostic value of the laboratory parameters of endothelial damage and coagulopathy in patients with COVID-19 and non-COVID-19 ARDS.

Full description

Endothelial damage and coagulation activation at the lung microvascular level may play an important role in the physiopathology of the COVID-19 ARDS. The project aims to prospectively investigate both bedside pulmonary physiological markers and biological markers of coagulopathy and endothelial dysfunction in COVID-19 and non-COVID-19 ARDS patients.

Enrollment: 40 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age> 18 years old
• Invasive mechanical ventilation in place for less than 48 hours
• Severe or moderate ARDS (defined according to the Berlin classification)
• Virological confirmation by PCR of SARS-CoV-2 infection (ARDS COVID-19)
• Lack of virological confirmation by PCR of SARS-CoV-2 infection (ARDS not linked to COVID-19)
• Patient information

Exclusion criteria

• Massive pulmonary embolism
• Chronic respiratory failure under long-term oxygen therapy
• Dying patient

Trial design

40 participants in 2 patient groups

non-COVID-19 ARDS patients

Description:

20 patients with acute respiratory distress syndrome (ARDS) unrelated to COVID-19

Treatment:

Diagnostic Test: Endothelial activation / endothelial senescence

Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations

Diagnostic Test: alveolar dead-space quantification

COVID-19 ARDS patients

Description:

20 patients with acute respiratory distress syndrome (ARDS) linked to COVID-19

Treatment:

Diagnostic Test: Endothelial activation / endothelial senescence

Diagnostic Test: Coagulation activation and impaired fibrinolysis explorations

Diagnostic Test: alveolar dead-space quantification